Examination of single nucleotide polymorphisms (SNPs) in transient receptor potential (TRP) ion channels in chronic fatigue syndrome patients

Immunology and Immunogenetics Insights

Volumn 7, Issue , 2015, Pages 1-6

  Marshall Gradisnik, Sonya M ^a,b   Smith, Peter ^b   Brenu, Ekua W ^a,b   Nilius, Bernd ^c   Ramos, Sandra B ^a,b   Staines, Donald R ^b  

^a GRIFFITH UNIVERSITY   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

^c LABORATORY OF MOLECULAR AND CELLULAR SIGNALING   (Belgium)

Author keywords

Chronic fatigue syndrome; Single nucleotide polymorphisms; Transient receptor potential

Indexed keywords

MAMMALIA;

EID: 84929417599     PISSN: None     EISSN: 11786345     Source Type: Journal    
DOI: 10.4137/III.S25147     Document Type: Article

References (64)

1. Clapham DE. TRP channels as cellular sensors. Nature. 2003;426(6966):517–524.
2. Nilius B, Owsianik G, Voets T, Peters JA. Transient receptor potential cation channels in disease. Physiol Rev. 2007;87(1):165–217.
3. Nilius B, Owsianik G. The transient receptor potential family of ion channels. Genome Biol. 2011;12(3):218.
4. Nilius B, Szallasi A. Transient receptor potential channels as drug targets: from the science of basic research to the art of medicine. Pharmacol Rev. 2014;66(3): 676–814.
5. Nilius B, Biro T, Owsianik G. TRPV3: time to decipher a poorly understood family member! J Physiol. 2014;592(pt 2):295–304.
6. Nilius B, Biro T. TRPV3: a ‘more than skinny’ channel. Exp Dermatol. 2013;22(7): 447–452.
7. Nilius B, Voets T. The puzzle of TRPV4 channelopathies. EMBO Rep. 2013;14(2): 152–163.
8. Vennekens R, Menigoz A, Nilius B. TRPs in the brain. Rev Physiol Biochem Pharmacol. 2012;163:27–64.
9. Moran MM, McAlexander MA, Biro T, Szallasi A. Transient receptor potential channels as therapeutic targets. Nat Rev Drug Discov. 2011;10(8):601–620.
10. Nieto-Posadas A, Jara-Oseguera A, Rosenbaum T. TRP channel gating physiology. Curr Top Med Chem. 2011;11(17):2131–2150.
11. Fernandez-Sola J, Lluis Padierna M, Nogue Xarau S, Munne Mas P. [Chronic fatigue syndrome and multiple chemical hypersensitivity after insecticide exposure]. Med Clin. 2005;124(12):451–453.
12. Lavergne MR, Cole DC, Kerr K, Marshall LM. Functional impairment in chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivity. Can Fam Physician. 2010;56(2):e57–e65.
13. Brown MM, Jason LA. Functioning in individuals with chronic fatigue syndrome: increased impairment with co-occurring multiple chemical sensitivity and fibromyalgia. Dyn Med. 2007;6:6.
14. Lind R, Berstad A, Hatlebakk J, Valeur J. Chronic fatigue in patients with unexplained self-reported food hypersensitivity and irritable bowel syndrome: validation of a Norwegian translation of the Fatigue Impact Scale. Clin Exp Gastroenterol. 2013;6:101–107.
15. Aboudiab T, Leke L, Skonieczny M, Chouraki JP. [Are IgE-independent food hypersensitivity and chronic fatigue syndrome related?]. Arch Pediatr. 2004; 11(8):975–977.
16. Brunet JL, Fatoohi F, Liaudet AP, Cozon GJ. [Role of pathological delayed-type hypersensitivity in chronic fatigue syndrome: importance of the evaluation of lymphocyte activation by flow cytometry and the measurement of urinary neopterin]. Allerg Immunol. 2002;34(2):38–44.
17. Light AR, Bateman L, Jo D, et al. Gene expression alterations at baseline and following moderate exercise in patients with chronic fatigue syndrome and fibromyalgia syndrome. J Intern Med. 2012;271(1):64–81.
18. Gees M, Owsianik G, Nilius B, Voets T. TRP channels. Compr Physiol. 2012;2(1): 563–608.
19. Nilius B, Owsianik G. Transient receptor potential channelopathies. Pflugers Arch. 2010;460(2):437–450.
20. Harvard. PLINK Whole Genome Association Analysis Toolset; 2014. Available at: http://pngu.mgh.harvard.edu/purcell/plink/
21. Freichel M, Tsvilovskyy V, Camacho-Londono JE. TRPC4- and TRPC4- containing channels. Handb Exp Pharmacol. 2014;222:85–128.
22. Lewis RS. Calcium signaling mechanisms in T lymphocytes. Annu Rev Immunol. 2001;19:497–521.
23. Brenu EW, Huth TK, Hardcastle SL, et al. Role of adaptive and innate immune cells in chronic fatigue syndrome/myalgic encephalomyelitis. Int Immunol. 2014; 26(4):233–242.
24. Brenu EW, Ashton KJ, van Driel M, et al. Cytotoxic lymphocyte microRNAs as prospective biomarkers for chronic fatigue syndrome/myalgic encephalomyelitis. J Affect Disord. 2012;141(2–3):261–269.
25. Brenu EW, van Driel ML, Staines DR, et al. Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome/myalgic encephalomyelitis. J Transl Med. 2012;10:88.
26. Brenu EW, van Driel ML, Staines DR, et al. Immunological abnormalities as potential biomarkers in chronic fatigue syndrome/myalgic encephalomyelitis. J Transl Med. 2011;9:81.
27. Brenu EW, Staines DR, Baskurt OK, et al. Immune and hemorheological changes in chronic fatigue syndrome. J Transl Med. 2010;8:1.
28. Barker E, Fujimura SF, Fadem MB, Landay AL, Levy JA. Immunologic abnormalities associated with chronic fatigue syndrome. Clin Infect Dis. 1994;18(suppl 1): S136–S141.
29. Zhang Z, Seguela P. Metabotropic induction of persistent activity in layers II/III of anterior cingulate cortex. Cereb Cortex. 2010;20(12):2948–2957.
30. Zhang Z, Reboreda A, Alonso A, Barker PA, Seguela P. TRPC channels underlie cholinergic plateau potentials and persistent activity in entorhinal cortex. Hippocampus. 2011;21(4):386–397.
31. Rainville P. Brain mechanisms of pain affect and pain modulation. Curr Opin Neurobiol. 2002;12(2):195–204.
32. Sewards TV, Sewards MA. The medial pain system: neural representations of the motivational aspect of pain. Brain Res Bull. 2002;59(3):163–180.
33. Yan HD, Villalobos C, Andrade R. TRPC channels mediate a muscarinic receptor-induced after depolarization in cerebral cortex. J Neurosci. 2009;29(32): 10038–10046.
34. Caseras X, Mataix-Cols D, Giampietro V, et al. Probing the working memory system in chronic fatigue syndrome: a functional magnetic resonance imaging study using the n-back task. Psychosom Med. 2006;68(6):947–955.
35. Caseras X, Mataix-Cols D, Rimes KA, et al. The neural correlates of fatigue: an exploratory imaginal fatigue provocation study in chronic fatigue syndrome. Psychol Med. 2008;38(7):941–951.
36. Nakatomi Y, Mizuno K, Ishii A, et al. Neuroinflammation in patients with chronic fatigue syndrome/myalgic encephalomyelitis: an 11C-(R)-PK11195 PET Study. J Nucl Med. 2014;55(6):945–950.
37. Tsvilovskyy VV, Zholos AV, Aberle T, et al. Deletion of TRPC4 and TRPC6 in mice impairs smooth muscle contraction and intestinal motility in vivo. Gastroenterology. 2009;137(4):1415–1424.
38. Lakhan SE, Kirchgessner A. Gut inflammation in chronic fatigue syndrome. Nutr Metab. 2010;7:79.
39. Kim H, Kim J, Jeon JP, et al. The roles of G proteins in the activation of TRPC4 and TRPC5 transient receptor potential channels. Channels. 2012;6(5): 333–343.
40. Bautista DM, Pellegrino M, Tsunozaki M. TRPA1: a gatekeeper for inflammation. Annu Rev Physiol. 2013;75:181–200.
41. Wang S, Dai Y, Fukuoka T, et al. Phospholipase C and protein kinase A mediate bradykinin sensitization of TRPA1: a molecular mechanism of inflammatory pain. Brain. 2008;131(pt 5):1241–1251.
42. Wilson SR, Gerhold KA, Bifolck-Fisher A, et al. TRPA1 is required for histamine-independent, Mas-related G protein-coupled receptor-mediated itch. Nat Neurosci. 2011;14(5):595–602.
43. Nilius B, Prenen J, Owsianik G. Irritating channels: the case of TRPA1. J Physiol. 2011;589(pt 7):1543–1549.
44. Wagner TF, Loch S, Lambert S, et al. Transient receptor potential M3 channels are ionotropic steroid receptors in pancreatic beta cells. Nat Cell Biol. 2008; 10(12):1421–1430.
45. Schütz M, Oertel BG, Heimann D, et al. Consequences of a human TRPA1 genetic variant on the perception of nociceptive and olfactory stimuli. PLoS One. 2014;9(4):e95592.
46. Shigetomi E, Tong X, Kwan KY, Corey DP, Khakh BS. TRPA1 channels regulate astrocyte resting calcium and inhibitory synapse efficacy through GAT-3. Nat Neurosci. 2012;15(1):70–80.
47. Nassini R, Materazzi S, Vriens J, et al. The ‘headache tree’ via umbellulone and TRPA1 activates the trigeminovascular system. Brain. 2012;135(pt 2): 376–390.
48. Garrison SR, Stucky CL. The dynamic TRPA1 channel: a suitable pharmacological pain target? Curr Pharm Biotechnol. 2011;12(10):1689–1697.
49. Garrison SR, Stucky CL. Contribution of transient receptor potential ankyrin 1 to chronic pain in aged mice with complete Freund’s adjuvant-induced arthritis. Arthritis Rheumatol. 2014;66(9):2380–2390.
50. Fischer MJ, Balasuriya D, Jeggle P, et al. Direct evidence for functional TRPV1/ TRPA1 heteromers. Pflugers Arch. 2014;466(12):2229–2241.
51. Carreño O, Corominas R, Fernández-Morales J, et al. SNP variants within the vanilloid TRPV1 and TRPV3 receptor genes are associated with migraine in the Spanish population. Am J Med Genet B Neuropsychiatr Genet. 2012;159 part (1): 94–103.
52. Marincsak R, Toth BI, Czifra G, Szabo T, Kovacs L, Biro T. The analgesic drug, tramadol, acts as an agonist of the transient receptor potential vanilloid-1. Anesth Analg. 2008;106(6):1890–1896.
53. Andersson DA, Gentry C, Alenmyr L, et al. TRPA1 mediates spinal antinociception induced by acetaminophen and the cannabinoid delta(9)- tetrahydrocannabiorcol. Nat Commun. 2011;2:551.
54. De Petrocellis L, Vellani V, Schiano-Moriello A, et al. Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. J Pharmacol Exp Ther. 2008;325(3):1007–1015.
55. Oberwinkler J, Philipp SE. Trpm3. Handb Exp Pharmacol. 2014;222:427–459.
56. Thiel G, Muller I, Rossler OG. Signal transduction via TRPM3 channels in pancreatic beta-cells. J Mol Endocrinol. 2013;50(3):R75–R83.
57. Colsoul B, Vennekens R, Nilius B. Transient receptor potential cation channels in pancreatic beta cells. Rev Physiol Biochem Pharmacol. 2011;161:87–110.
58. Wagner TF, Drews A, Loch S, et al. TRPM3 channels provide a regulated influx pathway for zinc in pancreatic beta cells. Pflugers Arch. 2010;460(4):755–765.
59. Bennett TM, Mackay DS, Siegfried CJ, Shiels A. Mutation of the melastatin-related cation channel, TRPM3, underlies inherited cataract and glaucoma. PLoS One. 2014;9(8):e104000.
60. Wyller VB, Godang K, Morkrid L, Saul JP, Thaulow E, Walloe L. Abnormal thermoregulatory responses in adolescents with chronic fatigue syndrome: relation to clinical symptoms. Pediatrics. 2007;120(1):e129–e137.
61. Meeus M, Nijs J. Central sensitization: a biopsychosocial explanation for chronic widespread pain in patients with fibromyalgia and chronic fatigue syndrome. Clin Rheumatol. 2007;26(4):465–473.
62. Nilius B, Voets T. A TRP channel-steroid marriage. Nat Cell Biol. 2008;10(12): 1383–1384.
63. Drews A, Mohr F, Rizun O, et al. Structural requirements of steroidal agonists of transient receptor potential melastatin 3 (TRPM3) cation channels. Br J Pharmacol. 2014;171(4):1019–1032.
64. Zamudio-Bulcock PA, Everett J, Harteneck C, Valenzuela CF. Activation of steroid-sensitive TRPM3 channels potentiates glutamatergic transmission at cerebellar Purkinje neurons from developing rats. J Neurochem. 2011;119(3): 474–485.